Vaccinex, Inc. (VCNX)
OTCMKTS · Delayed Price · Currency is USD
1.000
0.00 (0.00%)
May 26, 2026, 1:19 PM EST
Vaccinex Employees
As of December 31, 2024, Vaccinex had 27 total employees, including 23 full-time and 4 part-time employees. The number of employees decreased by 13 or -32.50% compared to the previous year.
Employees
27
Change (1Y)
-13
Growth (1Y)
-32.50%
Revenue / Employee
$24,040
Profits / Employee
-$745,360
Market Cap
2.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 27 | -13 | -32.50% | 23 | 4 |
| Dec 31, 2023 | 40 | -3 | -6.98% | 37 | 3 |
| Dec 31, 2022 | 43 | 2 | 4.88% | 38 | 5 |
| Dec 31, 2021 | 41 | 1 | 2.50% | 39 | 2 |
| Dec 31, 2020 | 40 | -9 | -18.37% | 39 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LakeShore Biopharma | 573 |
| Adaptimmune Therapeutics | 506 |
| CASI Pharmaceuticals | 233 |
| Eloxx Pharmaceuticals | 10 |
| Iterum Therapeutics | 9 |
| AXIM Biotechnologies | 7 |
| Hepion Pharmaceuticals | 2 |
Vaccinex News
- 27 days ago - Vaccinex Reports 2025 Annual Financial Results - GlobeNewsWire
- 5 months ago - Vaccinex announces $60M revenue sharing agreement with PDV - TheFly
- 1 year ago - Vaccinex to reports new clinical results on pepinemab at ASCO meeting - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - GlobeNewsWire
- 1 year ago - Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy - TheFly
- 1 year ago - Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR) - GlobeNewsWire
- 1 year ago - Vaccinex to delist common stock from Nasdaq - TheFly
- 1 year ago - Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market - GlobeNewsWire